Technical Analysis for PHAR - Pharming Group N.V.

Grade Last Price % Change Price Change
F 7.36 -4.15% -0.32
PHAR closed up 1.78 percent on Wednesday, November 20, 2024, on 1.22 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup -4.15%
Narrow Range Bar Range Contraction -4.15%
Lower Bollinger Band Walk Weakness -4.15%
Stochastic Reached Oversold Weakness -4.15%
Outside Day Range Expansion -4.15%
Oversold Stochastic Weakness -4.15%
NR7 Range Contraction -2.45%
NR7-2 Range Contraction -2.45%
Narrow Range Bar Range Contraction -2.45%
Gapped Down Weakness -2.45%

   Recent Intraday Alerts

Alert Time
1.5x Volume Pace about 1 hour ago
Down 3% about 1 hour ago
Fell Below Lower Bollinger Band about 1 hour ago
Slingshot Bearish Entry about 1 hour ago
Fell Below Previous Day's Low about 1 hour ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Pharming Group N.V. Description

Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Pharmaceutical Biology Drug Discovery Angioedema Complement System Hereditary Angioedema Biopharmaceutical Products Acute Kidney Injury Complement Deficiency Pharming C1 Inhibitor Haemophilia

Is PHAR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.2
52 Week Low 6.65
Average Volume 6,788
200-Day Moving Average 9.12
50-Day Moving Average 8.27
20-Day Moving Average 8.24
10-Day Moving Average 7.96
Average True Range 0.46
RSI (14) 41.18
ADX 9.81
+DI 20.00
-DI 21.10
Chandelier Exit (Long, 3 ATRs) 8.17
Chandelier Exit (Short, 3 ATRs) 8.85
Upper Bollinger Bands 9.03
Lower Bollinger Band 7.45
Percent B (%b) 0.15
BandWidth 19.16
MACD Line -0.19
MACD Signal Line -0.10
MACD Histogram -0.0849
Fundamentals Value
Market Cap 506.25 Million
Num Shares 65.9 Million
EPS -0.33
Price-to-Earnings (P/E) Ratio -23.27
Price-to-Sales 3.38
Price-to-Book 3.77
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.01
Resistance 3 (R3) 7.97 7.83 7.96
Resistance 2 (R2) 7.83 7.74 7.85 7.94
Resistance 1 (R1) 7.75 7.69 7.79 7.79 7.92
Pivot Point 7.61 7.61 7.63 7.63 7.61
Support 1 (S1) 7.53 7.52 7.57 7.57 7.44
Support 2 (S2) 7.39 7.47 7.41 7.42
Support 3 (S3) 7.31 7.39 7.41
Support 4 (S4) 7.35